Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION Clinical-development physician is responsible for the 505(b)(2) bridge is in an RWE group proposing a post-marketing study instead of a new RCT, using 505(b)(2) literature-to-product bridge table as the only working extract. A CMO 483 that maps to the NDA CMC module is what reset the timeline for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a CMO 483 that maps to the NDA CMC module for clinical-development physician. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision the 505(b)(2) bridge is turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the 505(b)(2) bridge is for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for clinical-development physician - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - CMC and Development Pathways finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform - Missing page in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module, if any